Please ensure Javascript is enabled for purposes of website accessibility

Why ViewRay Crushed the Market on Thursday

By Eric Volkman - Jun 24, 2021 at 6:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced an exciting new deal with a major specialist company from Down Under.

What happened

Thursday was a fine day for radiation therapy device maker ViewRay (VRAY 3.92%) and its shareholders. The company announced a new supply deal that sent its stock price nearly 12% higher.

So what

ViewRay and Australian privately-held oncology and cardiac healthcare services company GenesisCare announced jointly that they have entered into a master purchase agreement. Under the terms of the deal, GenesisCare will buy up to 14 of ViewRay's MRIdian MR-Guided Therapy Systems for its operations in both the U.K. and in Ft. Myers, Florida. This will give GenesisCare the capacity to provide radiation therapy to patients at three of its treatment centers in the former country, in addition to the U.S. location.

Neither company revealed the price nor the leading terms of the arrangement.

A doctor in a consultation with a person holding a tablet.

Image source: Getty Images.

Regardless, GenesisCare is a major "get" for the relatively small and specialized ViewRay. According to the two companies, GenesisCare is the world's No. 1 provider of cancer services. It has over 440 oncology and heart care centers, and it's represented throughout the world with operations in its native Australia, Europe, and the U.S. The companies said that GenesisCare treats over 400,000 patients annually.

Now what

Without knowing the financial particulars of the deal, it's tough to judge how it will affect ViewRay's fundamentals. Yet it almost doesn't matter; GenesisCare is a large and powerful player in its segment, and if ViewRay can make it a satisfied customer the Australian company might end up being an important and regular source of revenue for years to come.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ViewRay, Inc. Stock Quote
ViewRay, Inc.
VRAY
$3.71 (3.92%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.